Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)

Next Previous
X
Search
Trial Profile

An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 13 Aug 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lasmiditan (Primary)
  • Indications Migraine
  • Focus Adverse reactions; Registrational
  • Acronyms GLADIATOR
  • Sponsors CoLucid Pharmaceuticals; Eli Lilly and Company

    • Most Recent Events

    • 06 Aug 2021 Results of post hoc analyses used data from 3 Phase III randomized trials, SAMURAI, SPARTAN and GLADIATOR published in the Clinical Therapeutics
    • 01 May 2021 Results of a pooled analysis of 3 trials (SAMURAI; SPARTAN and GLADIATOR) assessing the efficacy and safety of lasmiditan in patients who treated two migraine attacks with the same or different lasmiditan doses has been published in the Postgraduate Medicine.
    • 22 Apr 2021 Results (n=1981) assessing the efficacy of lasmiditan in treating migraine attacks of mild versus moderate or severe pain severity presented at the 73rd Annual Meeting of the American Academy of Neurology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top